Beyond Chicken Eggs: Flu Shots Get mRNA Boost

For decades, flu vaccines have been cultivated in chicken eggs, a method that, while effective, struggles to keep pace with the rapidly mutating influenza virus. This traditional process takes six months, often leading to a mismatch between the vaccine and circulating strains. Scientists are now exploring modern alternatives to improve vaccine responsiveness and effectiveness.

Emerging research highlights the promise of mRNA technology, similar to that used in COVID-19 vaccines. Phase 3 trials indicate these mRNA flu shots offer a significant increase in protection compared to egg-based vaccines. While initial side effects like temporary fatigue were more prevalent, the potential for better, more rapid adaptation to new virus strains is a major advantage.

Beyond mRNA, other non-egg based technologies are advancing, including cell-based and recombinant vaccines. These methods aim to bypass the limitations of avian cells and accelerate production, offering greater flexibility in vaccine strain selection closer to flu season and potentially securing a more robust global supply.